These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35443747)

  • 1. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.
    Wang Y; Liu M; Shen Y; Ma Y; Li X; Zhang Y; Liu M; Yang XL; Chen J; Yan R; Luan D; Wang Y; Chen Y; Wang Q; Lin H; Li Y; Wu K; Zhu T; Zhao J; Lu H; Wen Y; Jiang S; Wu F; Zhou Q; Shi ZL; Huang J
    Cell Discov; 2022 Apr; 8(1):36. PubMed ID: 35443747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
    Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
    Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
    Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
    J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
    Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
    J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
    Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
    Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents.
    Cao Y; Jian F; Zhang Z; Yisimayi A; Hao X; Bao L; Yuan F; Yu Y; Du S; Wang J; Xiao T; Song W; Zhang Y; Liu P; An R; Wang P; Wang Y; Yang S; Niu X; Zhang Y; Gu Q; Shao F; Hu Y; Yin W; Zheng A; Wang Y; Qin C; Jin R; Xiao J; Xie XS
    Cell Rep; 2022 Dec; 41(12):111845. PubMed ID: 36493787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
    Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
    One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
    Li S; Wu J; Jiang W; He H; Zhou Y; Wu W; Gao Y; Xie M; Xia A; He J; Zhang Q; Han Y; Wang N; Zhu G; Wang Q; Zhang Z; Mayer CT; Wang K; Wang X; Wang J; Chen Z; Jiang S; Sun L; Xia R; Wang Q
    J Med Virol; 2023 Feb; 95(2):e28440. PubMed ID: 36573441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses.
    He WT; Musharrafieh R; Song G; Dueker K; Tse LV; Martinez DR; Schäfer A; Callaghan S; Yong P; Beutler N; Torres JL; Volk RM; Zhou P; Yuan M; Liu H; Anzanello F; Capozzola T; Parren M; Garcia E; Rawlings SA; Smith DM; Wilson IA; Safonova Y; Ward AB; Rogers TF; Baric RS; Gralinski LE; Burton DR; Andrabi R
    bioRxiv; 2022 Feb; ():. PubMed ID: 35169804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain.
    Wang Y; Zhang Z; Yang M; Xiong X; Yan Q; Cao L; Wei P; Zhang Y; Zhang L; Lv K; Chen J; Liu X; Zhao X; Xiao J; Zhang S; Zhu A; Gan M; Zhang J; Cai R; Zhuo J; Zhang Y; Rao H; Qu B; Zhang Y; Chen L; Dai J; Cheng L; Hu Q; Chen Y; Lv H; So RTY; Peiris M; Zhao J; Liu X; Mok CKP; Wang X; Zhao J
    Cell Rep; 2024 Jan; 43(1):113653. PubMed ID: 38175758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2.
    Feng Y; Yuan M; Powers JM; Hu M; Munt JE; Arunachalam PS; Leist SR; Bellusci L; Adams LE; Sundaramurthy S; Shirreff LM; Mallory ML; Scooby TD; Moreno A; O'Hagan DT; Kleanthous H; Villinger FJ; Veesler D; King NP; Suthar MS; Khurana S; Baric RS; Wilson IA; Pulendran B
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor.
    Chia WN; Tan CW; Tan AWK; Young B; Starr TN; Lopez E; Fibriansah G; Barr J; Cheng S; Yeoh AY; Yap WC; Lim BL; Ng TS; Sia WR; Zhu F; Chen S; Zhang J; Kwek MSS; Greaney AJ; Chen M; Au GG; Paradkar PN; Peiris M; Chung AW; Bloom JD; Lye D; Lok S; Wang LF
    Sci Adv; 2023 Jul; 9(30):eade3470. PubMed ID: 37494438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines.
    Zhou J; Liu Z; Zhang G; Xu W; Xing L; Lu L; Wang Q; Jiang S
    J Med Virol; 2023 Jan; 95(1):e28172. PubMed ID: 36161303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses.
    Wang P; Casner RG; Nair MS; Yu J; Guo Y; Wang M; Chan JF; Cerutti G; Iketani S; Liu L; Sheng Z; Chen Z; Yuen KY; Kwong PD; Huang Y; Shapiro L; Ho DD
    bioRxiv; 2021 Oct; ():. PubMed ID: 34671769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.
    Ruiz F; Foreman W; Lilly M; Baharani VA; Depierreux DM; Chohan V; Taylor AL; Guenthoer J; Ralph D; Matsen FA; Chu HY; Bieniasz PD; Côté M; Starr TN; Overbaugh J
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates.
    Malewana RD; Stalls V; May A; Lu X; Martinez DR; Schäfer A; Li D; Barr M; Sutherland LL; Lee E; Parks R; Beck WE; Newman A; Bock KW; Minai M; Nagata BM; DeMarco CT; Denny TN; Oguin TH; Rountree W; Wang Y; Mansouri K; Edwards RJ; Sempowski GD; Eaton A; Muramatsu H; Henderson R; Tam Y; Barbosa C; Tang J; Cain DW; Santra S; Moore IN; Andersen H; Lewis MG; Golding H; Seder R; Khurana S; Montefiori DC; Pardi N; Weissman D; Baric RS; Acharya P; Haynes BF; Saunders KO
    bioRxiv; 2023 Dec; ():. PubMed ID: 38187726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies.
    Zhang F; Jenkins J; de Carvalho RVH; Nakandakari-Higa S; Chen T; Abernathy ME; Baharani VA; Nyakatura EK; Andrew D; Lebedeva IV; Lorenz IC; Hoffmann HH; Rice CM; Victora GD; Barnes CO; Hatziioannou T; Bieniasz PD
    Nat Microbiol; 2023 Jun; 8(6):1051-1063. PubMed ID: 37188812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses.
    He WT; Musharrafieh R; Song G; Dueker K; Tse LV; Martinez DR; Schäfer A; Callaghan S; Yong P; Beutler N; Torres JL; Volk RM; Zhou P; Yuan M; Liu H; Anzanello F; Capozzola T; Parren M; Garcia E; Rawlings SA; Smith DM; Wilson IA; Safonova Y; Ward AB; Rogers TF; Baric RS; Gralinski LE; Burton DR; Andrabi R
    Nat Immunol; 2022 Jun; 23(6):960-970. PubMed ID: 35654851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.